共 50 条
- [31] T6496 targeting EGFR mediated by T790M or C797S mutant: machine learning, virtual screening and bioactivity evaluation studyJOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2025, 43 (06): : 3144 - 3155Wang, Linxiao论文数: 0 引用数: 0 h-index: 0机构: Jiangxi Sci & Technol Normal Univ, Sch Pharm, Jiangxi Prov Key Lab Drug Design & Evaluat, Nanchang, Peoples R China Jiangxi Sci & Technol Normal Univ, Sch Pharm, Jiangxi Prov Key Lab Drug Design & Evaluat, Nanchang, Peoples R ChinaFan, Dang论文数: 0 引用数: 0 h-index: 0机构: Jiangxi Sci & Technol Normal Univ, Sch Pharm, Jiangxi Prov Key Lab Drug Design & Evaluat, Nanchang, Peoples R China Jiangxi Sci & Technol Normal Univ, Sch Pharm, Jiangxi Prov Key Lab Drug Design & Evaluat, Nanchang, Peoples R ChinaRuan, Wei论文数: 0 引用数: 0 h-index: 0机构: Jiangxi Sci & Technol Normal Univ, Sch Pharm, Jiangxi Prov Key Lab Drug Design & Evaluat, Nanchang, Peoples R China Jiangxi Sci & Technol Normal Univ, Sch Pharm, Jiangxi Prov Key Lab Drug Design & Evaluat, Nanchang, Peoples R ChinaHuang, Xiaoling论文数: 0 引用数: 0 h-index: 0机构: Jiangxi Sci & Technol Normal Univ, Sch Pharm, Jiangxi Prov Key Lab Drug Design & Evaluat, Nanchang, Peoples R China Jiangxi Sci & Technol Normal Univ, Sch Pharm, Jiangxi Prov Key Lab Drug Design & Evaluat, Nanchang, Peoples R ChinaZhu, Wufu论文数: 0 引用数: 0 h-index: 0机构: Jiangxi Sci & Technol Normal Univ, Sch Pharm, Jiangxi Prov Key Lab Drug Design & Evaluat, Nanchang, Peoples R China Jiangxi Sci & Technol Normal Univ, Sch Pharm, Jiangxi Prov Key Lab Drug Design & Evaluat, Nanchang, Peoples R ChinaTu, Yuanbiao论文数: 0 引用数: 0 h-index: 0机构: Jiangxi Univ Tradit Chinese Med, Canc Res Ctr, Nanchang, Peoples R China Jiangxi Sci & Technol Normal Univ, Sch Pharm, Jiangxi Prov Key Lab Drug Design & Evaluat, Nanchang, Peoples R ChinaZheng, Pengwu论文数: 0 引用数: 0 h-index: 0机构: Jiangxi Sci & Technol Normal Univ, Sch Pharm, Jiangxi Prov Key Lab Drug Design & Evaluat, Nanchang, Peoples R China Jiangxi Sci & Technol Normal Univ, Sch Pharm, Jiangxi Prov Key Lab Drug Design & Evaluat, Nanchang, Peoples R China
- [33] Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutationBIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 30 (16)Su, Zhicheng论文数: 0 引用数: 0 h-index: 0机构: East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R China East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R ChinaYang, Tingyuan论文数: 0 引用数: 0 h-index: 0机构: East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R China East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R ChinaWang, Jie论文数: 0 引用数: 0 h-index: 0机构: East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R China East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R ChinaLai, Mengzhen论文数: 0 引用数: 0 h-index: 0机构: Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Shanghai 201203, Peoples R China Fudan Univ, Sch Pharm, Shanghai 201203, Peoples R China East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R ChinaTong, Linjiang论文数: 0 引用数: 0 h-index: 0机构: Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Shanghai 201203, Peoples R China East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R ChinaWumaier, Gulinuer论文数: 0 引用数: 0 h-index: 0机构: Fudan Univ, Huashan Hosp, Dept Pulm & Crit Care Med, Shanghai, Peoples R China East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R ChinaChen, Zhuo论文数: 0 引用数: 0 h-index: 0机构: East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R China East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R ChinaLi, Shengqing论文数: 0 引用数: 0 h-index: 0机构: Fudan Univ, Huashan Hosp, Dept Pulm & Crit Care Med, Shanghai, Peoples R China East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R ChinaLi, Honglin论文数: 0 引用数: 0 h-index: 0机构: East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R China East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R ChinaXie, Hua论文数: 0 引用数: 0 h-index: 0机构: Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Shanghai 201203, Peoples R China East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R ChinaZhao, Zhenjiang论文数: 0 引用数: 0 h-index: 0机构: East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R China East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R China
- [34] Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790MNature Medicine, 2015, 21 : 560 - 562Kenneth S Thress论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca,Department of Medical OncologyCloud P Paweletz论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca,Department of Medical OncologyEnriqueta Felip论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca,Department of Medical OncologyByoung Chul Cho论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca,Department of Medical OncologyDaniel Stetson论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca,Department of Medical OncologyBrian Dougherty论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca,Department of Medical OncologyZhongwu Lai论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca,Department of Medical OncologyAleksandra Markovets论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca,Department of Medical OncologyAna Vivancos论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca,Department of Medical OncologyYanan Kuang论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca,Department of Medical OncologyDalia Ercan论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca,Department of Medical OncologySarah E Matthews论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca,Department of Medical OncologyMireille Cantarini论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca,Department of Medical OncologyJ Carl Barrett论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca,Department of Medical OncologyPasi A Jänne论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca,Department of Medical OncologyGeoffrey R Oxnard论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca,Department of Medical Oncology
- [35] The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion MutationsJTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (03):Kagawa, Yosuke论文数: 0 引用数: 0 h-index: 0机构: Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Japan Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Translat Genom, Kashiwa, Japan Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Mol & Internal Med, Hiroshima, Japan Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, JapanHayashida, Takuma论文数: 0 引用数: 0 h-index: 0机构: Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Translat Genom, Kashiwa, Japan Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Kashiwa, Japan Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, JapanLiu, Jie论文数: 0 引用数: 0 h-index: 0机构: Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Translat Genom, Kashiwa, Japan Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, JapanMori, Shunta论文数: 0 引用数: 0 h-index: 0机构: Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Japan Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, JapanIzumi, Hiroki论文数: 0 引用数: 0 h-index: 0机构: Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Japan Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, JapanKumagai, Shogo论文数: 0 引用数: 0 h-index: 0机构: Natl Canc Ctr, Res Inst, Exploratory Oncol Res & Clin Trial Ctr, Div Canc Immunol, Kashiwa, Japan Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, JapanUdagawa, Hibiki论文数: 0 引用数: 0 h-index: 0机构: Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Japan Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Translat Genom, Kashiwa, Japan Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, JapanHattori, Noboru论文数: 0 引用数: 0 h-index: 0机构: Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Mol & Internal Med, Hiroshima, Japan Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, JapanGoto, Koichi论文数: 0 引用数: 0 h-index: 0机构: Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Japan Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, JapanKobayashi, Susumu S.论文数: 0 引用数: 0 h-index: 0机构: Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Translat Genom, Kashiwa, Japan Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Kashiwa, Japan Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA Beth Israel Deconess Med Ctr, Dept Med, Boston, MA 02215 USA Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Japan
- [36] CH7233163, a mutantselective EGFR inhibitor, overcomes osimertinib resistant EGFR-T790M/C797SCANCER RESEARCH, 2020, 80 (16)Kashima, Kenji论文数: 0 引用数: 0 h-index: 0机构: CHUGAI PHARMACEUT CO LTD, Kamakura, Kanagawa, Japan CHUGAI PHARMACEUT CO LTD, Kamakura, Kanagawa, Japan
- [37] Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790MNATURE MEDICINE, 2015, 21 (06) : 560 - 562Thress, Kenneth S.论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca, Waltham, MA USA AstraZeneca, Waltham, MA USAPaweletz, Cloud P.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA AstraZeneca, Waltham, MA USAFelip, Enriqueta论文数: 0 引用数: 0 h-index: 0机构: Vall dHebron Inst Oncol, Barcelona, Spain Vall dHebron Univ Hosp, Barcelona, Spain AstraZeneca, Waltham, MA USACho, Byoung Chul论文数: 0 引用数: 0 h-index: 0机构: Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea AstraZeneca, Waltham, MA USAStetsonl, Daniel论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca, Waltham, MA USA AstraZeneca, Waltham, MA USADougherty, Brian论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca, Waltham, MA USA AstraZeneca, Waltham, MA USALai, Zhongwu论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca, Waltham, MA USA AstraZeneca, Waltham, MA USAMarkovets, Aleksandra论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca, Waltham, MA USA AstraZeneca, Waltham, MA USAVivancos, Ana论文数: 0 引用数: 0 h-index: 0机构: Vall dHebron Inst Oncol, Barcelona, Spain AstraZeneca, Waltham, MA USAKuang, Yanan论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA AstraZeneca, Waltham, MA USAErcan, Dalia论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA AstraZeneca, Waltham, MA USAMatthews, Sarah E.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA AstraZeneca, Waltham, MA USACantarini, Mireille论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca, Macclesfield, Cheshire, England AstraZeneca, Waltham, MA USABarrett, J. Carl论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca, Waltham, MA USA AstraZeneca, Waltham, MA USAJaenne, Pasi A.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA AstraZeneca, Waltham, MA USAOxnard, Geoffrey R.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA AstraZeneca, Waltham, MA USA
- [38] TAS3351, a fourth-generation brain-penetrating EGFR inhibitor designed to target common EGFR mutations, including those with or without T790M and C797S resistance mutationsEUROPEAN JOURNAL OF CANCER, 2024, 211 : S26 - S28Iwasaki, J.论文数: 0 引用数: 0 h-index: 0机构: TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, Japan TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, JapanKasuga, H.论文数: 0 引用数: 0 h-index: 0机构: TAIHO Phamaceut Co Ltd, Corp Planning Dept, Tokyo, Japan TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, JapanKataoka, Y.论文数: 0 引用数: 0 h-index: 0机构: TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, Japan TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, JapanMuraoka, H.论文数: 0 引用数: 0 h-index: 0机构: TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, Japan TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, JapanYamamoto, F.论文数: 0 引用数: 0 h-index: 0机构: TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, Japan TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, JapanTsuji, S.论文数: 0 引用数: 0 h-index: 0机构: TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, Japan TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, JapanTanaka, S.论文数: 0 引用数: 0 h-index: 0机构: TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, Japan TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, JapanHashimoto, A.论文数: 0 引用数: 0 h-index: 0机构: TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, Japan TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, JapanMiyamoto, R.论文数: 0 引用数: 0 h-index: 0机构: TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, Japan TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, JapanMizuarai, S.论文数: 0 引用数: 0 h-index: 0机构: TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, Japan TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, JapanOhkubo, S.论文数: 0 引用数: 0 h-index: 0机构: TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, Japan TAIHO Phamaceut Co Ltd, Discovery & Preclin Res Div, Tsukuba, Ibaraki, Japan
- [39] BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLCANNALS OF ONCOLOGY, 2020, 31 : S839 - S839Schalm, S. S.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Global Headquarters, Biol, Cambridge, MA USA Blueprint Med Global Headquarters, Biol, Cambridge, MA USADineen, T.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Global Headquarters, Biol, Cambridge, MA USA Blueprint Med Global Headquarters, Biol, Cambridge, MA USALim, S. M.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Global Headquarters, Biol, Cambridge, MA USAPark, C-W.论文数: 0 引用数: 0 h-index: 0机构: Yonsei Univ, Coll Med, Yonsei Canc Ctr, Med Oncol, Seoul, South Korea Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea Blueprint Med Global Headquarters, Biol, Cambridge, MA USAHsieh, J.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Global Headquarters, Biol, Cambridge, MA USA Blueprint Med Global Headquarters, Biol, Cambridge, MA USAWoessner, R.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Global Headquarters, Biol, Cambridge, MA USA Blueprint Med Global Headquarters, Biol, Cambridge, MA USAZhang, Z.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Global Headquarters, Biol, Cambridge, MA USA Blueprint Med Global Headquarters, Biol, Cambridge, MA USAWilson, K.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Global Headquarters, Biol, Cambridge, MA USA Blueprint Med Global Headquarters, Biol, Cambridge, MA USAEno, M.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Global Headquarters, Biol, Cambridge, MA USA Blueprint Med Global Headquarters, Biol, Cambridge, MA USAWilson, D.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Global Headquarters, Biol, Cambridge, MA USA Blueprint Med Global Headquarters, Biol, Cambridge, MA USAWilliams, B.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Global Headquarters, Biol, Cambridge, MA USA Blueprint Med Global Headquarters, Biol, Cambridge, MA USACampbell, J.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Global Headquarters, Biol, Cambridge, MA USA Blueprint Med Global Headquarters, Biol, Cambridge, MA USADe Savi, C.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Global Headquarters, Biol, Cambridge, MA USA Blueprint Med Global Headquarters, Biol, Cambridge, MA USAStevison, F.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Global Headquarters, Biol, Cambridge, MA USA Blueprint Med Global Headquarters, Biol, Cambridge, MA USAUtt, C.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Global Headquarters, Biol, Cambridge, MA USA Blueprint Med Global Headquarters, Biol, Cambridge, MA USAGuzi, T.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Global Headquarters, Biol, Cambridge, MA USA Blueprint Med Global Headquarters, Biol, Cambridge, MA USADorsch, M.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Global Headquarters, Biol, Cambridge, MA USA Blueprint Med Global Headquarters, Biol, Cambridge, MA USAHoeflich, K.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Global Headquarters, Biol, Cambridge, MA USA Blueprint Med Global Headquarters, Biol, Cambridge, MA USACho, B. C. Chul论文数: 0 引用数: 0 h-index: 0机构: Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea Blueprint Med Global Headquarters, Biol, Cambridge, MA USA
- [40] BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLCANNALS OF ONCOLOGY, 2020, 31 : S1391 - S1391Schalm, S. S.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Corp, Cambridge, MA USA Blueprint Med Corp, Cambridge, MA USADineen, T.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Corp, Cambridge, MA USA Blueprint Med Corp, Cambridge, MA USALim, S. M.论文数: 0 引用数: 0 h-index: 0机构: Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea Blueprint Med Corp, Cambridge, MA USAPark, C. W.论文数: 0 引用数: 0 h-index: 0机构: Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea Blueprint Med Corp, Cambridge, MA USAHsieh, J.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Corp, Cambridge, MA USA Blueprint Med Corp, Cambridge, MA USAWoessner, R.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Corp, Cambridge, MA USA Blueprint Med Corp, Cambridge, MA USAZhang, Z.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Corp, Cambridge, MA USA Blueprint Med Corp, Cambridge, MA USAWilson, K.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Corp, Cambridge, MA USA Blueprint Med Corp, Cambridge, MA USAEno, M.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Corp, Cambridge, MA USA Blueprint Med Corp, Cambridge, MA USAWilson, D.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Corp, Cambridge, MA USA Blueprint Med Corp, Cambridge, MA USAWilliams, B.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Corp, Cambridge, MA USA Blueprint Med Corp, Cambridge, MA USACampbell, J.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Corp, Cambridge, MA USA Blueprint Med Corp, Cambridge, MA USAde Savi, C.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Corp, Cambridge, MA USA Blueprint Med Corp, Cambridge, MA USAStevison, F.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Corp, Cambridge, MA USA Blueprint Med Corp, Cambridge, MA USAUtt, C.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Corp, Cambridge, MA USA Blueprint Med Corp, Cambridge, MA USAGuzi, T.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Corp, Cambridge, MA USA Blueprint Med Corp, Cambridge, MA USADorsch, M.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Corp, Cambridge, MA USA Blueprint Med Corp, Cambridge, MA USAHoeflich, K.论文数: 0 引用数: 0 h-index: 0机构: Blueprint Med Corp, Cambridge, MA USA Blueprint Med Corp, Cambridge, MA USACho, B. C.论文数: 0 引用数: 0 h-index: 0机构: Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea Blueprint Med Corp, Cambridge, MA USA